Wiley deal further amendments

Kyle Brady
Friday 9 October 2020

The Jisc Wiley read and publish deal was introduced this year, the principal aim of which is to encourage publishers to move away from subscriptions to an open access business model. Read and publish deals such as this allow researchers at participating institutions to publish open access without having to pay the individual article open access fees, as the open access fees are paid up front to the publisher. Unlike other Read and Publish deals however the Wiley deal does not cover 100% of articles, but instead only intends to cover 85% of published output by participating institutions.

There is therefore a finite pot of money that Jisc is monitoring on institutions’ behalf. Jisc identified early on that the pot was being used up too quickly, so they and Wiley agreed to restrict use of the funds to certain article types – see our previous blog post here for more details on this.

Jisc have again identified that the pot is still in danger of being used up long before the end of the year so they have further restricted the deal to research funded by UKRI and the Biomedical charities – Wellcome Trust, Blood Cancer UK, British Heart Foundation, Cancer Research UK, Parkinson’s UK and Versus Arthritis.

The new restrictions come into effect on 12th October 2020, but any research article accepted before this date will still be made Open Access under the deal regardless of funding acknowledged.

If you have any questions or concerns about this do get in touch, similarly if you have an article in submission to a Wiley journal currently and you’d like to check your options regarding open access do get in touch with us.


Leave a reply

By using this form you agree with the storage and handling of your data by this website.

Contact us

Open Research
Walter Bower House
Eden Campus
Main Street
Guardbridge
St Andrews
KY16 0US
Fife, Scotland, UK

Open Access email:
[email protected]
Research Data email:
[email protected]

Phone: 01334 468851(OA) / 01334 462343(RDM)